European Biotech Acquisition Corp.

Status: Deal Closed
U=S+W/3 W=S@11.50
IPO Proceeds, $M $127.55M
IPO Date Mar 16, 2021
CEO Eduardo Bravo Fernandez de Araoz
Left Lead Credit Suisse
IPO Cash in Trust 100.0%
SPAC Tenor 24 months
IPO Sector Healthcare

Life Sciences Industry in Europe

IPO Geography Europe
Target Company Oculis
Deal Announced Oct 17, 2022
Deal Size, $M $218.00M
Deal Sector Healthcare
Deal Geography Global
SEC Filings www.sec.gov
Approval Vote Feb 28, 2023
Amendment Vote TBD
Closing Date Mar 2, 2023
Formerly EBAC OCS OCSAW

Sign up for Free Trial

No credit card required

Sign in for more on European Biotech Acquisition Corp.:

  • Structure and cap table
  • 6 directors & officers
  • 17 filings and events
  • 2 underwriters
  • 8 deal advisors
  • 5 legal advisors
Structure

Sign in to view structure, cap table, and calendar of events.

Team
Name Age Title
Eduardo Bravo Fernandez de Araoz 55 Chief Executive Officer
Koen Sintnicolaas 32 Chief Financial Officer
Martijn Kleijwegt 66 Director
Mark Wegter 51 Director
Volkert Doekson 58 Director
Onno van de Stolpe 61 Director

Sign in to view team biographies and more sponsor and affiliate data.

Advisors
Underwriters
Credit Suisse Joint BR 9,300,000 units
Kempen & Co. Joint BR 2,700,000
12,000,000 units
Up-Front UW fee 2.00 %
Deferred UW fee 3.50 %

Sign in to view more advisor data.

Deal

Sign in to view merger details and deal financials.

Filings

Sign in to view 17 filings.

Shareholders

Sign in to view shareholders 13F filing data.